Melinta Therapeutics, Inc. Watch

from 8-K 73 pages Restructuring Support Agreement Among Melinta Therapeutics, Inc. and the Supporting Lenders Identified Herein Dated as of December 27, 2019

from 8-K 20 pages Separation and Release Agreement

from 8-K 10 pages First Amendment

from 10-Q ~20 pages Melinta Therapeutics, Inc. Amended and Restated 2018 Stock Incentive Plan

from 10-Q Material contract

from 8-K 25 pages Employment Agreement

from 8-K 55 pages First Amendment to Facility Agreement

from DEFA14A 55 pages First Amendment to Facility Agreement

from 8-K 16 pages December 18, 2018 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, Connecticut 06511 Re: Financing Commitment Ladies and Gentlemen

from DEFA14A 16 pages December 18, 2018 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, Connecticut 06511 Re: Financing Commitment Ladies and Gentlemen

from 8-K 23 pages Purchase Agreement Dated as of November 19, 2018 by and Between Melinta Therapeutics, Inc. and Vatera Healthcare Partners LLC

from 10-Q 10 pages Amendment No. 2 to Exclusive License and Development Agreement

from 10-Q 21 pages License Agreement Between Melinta Therapeutics, Inc. and A. Menarini Industrie Farmaceutiche Riunite S.R.L. Dated as of September 29, 2018

from 10-Q 4 pages Re: Severance Agreement Dear Peter: Effective as of Your Commencement of Employment With Melinta Therapeutics, Inc. (The “Company”), You Will Be a Key Member of the Senior Management Team of the Company. as a Result, the Company Is Providing You With the Following Benefits in Consideration of Your Employment With the Company. I. Definitions. for the Purposes of This Severance Agreement (This “Agreement”), Capitalized Terms Shall Have the Following Meanings: 1. “Cause” Shall Mean: (A) Your Conviction of or Your Plea of Guilty to or Confession of an Act of Fraud, Misappropriation or Embezzlement or Any Felony; (B) Your Willful Refusal or Failure to Follow a Lawful Directive or Instruction of the Company’s Board of Directors or the Individual(s) to Whom You Report; (C) in Carrying Out Your Duties, You Commit Material Dishonesty or You Breach a Fiduciary Duty to the Company; (D) You Engage in Conduct Which Causes Material Injury to the Company, Monetarily or Otherwise; (E) You Use Illegal Substances at Any Time; or (F) You Materially Breach Any Company Policies Regarding Confidentiality, Insider Trading, Any Employment Agreement With the Company Then in Effect or Your Employee Noncompetition, Nondisclosure and Developments Agreement. 2. “Change in Control” Shall Mean the Date: (A) Any “Person” or “Group” (As Such Terms Are Used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as Amended) Is or Becomes the Beneficial Owner of Our Securities Representing 50% or More of the Total Voting Power of the Company’s Then-Outstanding

from 10-Q ~10 pages We Are Pleased to Offer You Employment at Melinta Therapeutics, Inc. ("Melinta" or the “Company”). Your Anticipated Start Date Will Be on or About September 17, 2018 (The “Commencement Date”). We Are Enthusiastic About the Prospect of Your Joining the Team, and Are Confident of a Mutually Beneficial Relationship. Position

from 8-K 10 pages November 6, 2018 Melinta Therapeutics, Inc. 300 George Street Suite 301 New Haven, Ct 06511 Re: Financing Commitment Ladies and Gentlemen

from 10-Q ~10 pages Melinta Therapeutics, Inc. Notice of Stock Option Grant

from 8-K 2 pages October 23, 2018 Mr. Daniel Mark Wechsler Address on File With the Company Dear Dan,

from 8-K 31 pages Employment Agreement

from 8-K 10 pages Separation and Release Agreement